Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity

OBJECTIVES: Nivolumab is used at 3 mg/kg or fixed doses of 240 mg every 2 weeks. There was no dose–response/toxicity relationship of nivolumab. This study evaluated the efficacy of low-dose nivolumab as an alternative to the financial toxicity of standard-dose nivolumab in treatment of non-small cel...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ESMO Open
Main Authors: Yoo, Shin Hye, Keam, Bhumsuk, Kim, Miso, Kim, Se Hyun, Kim, Yu Jung, Kim, Tae Min, Kim, Dong-Wan, Lee, Jong Seok, Heo, Dae Seog
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6069908/
https://ncbi.nlm.nih.gov/pubmed/30094065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2018-000332
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados